Akari Therapeutics PLC (AKTX) Rating Lowered to Hold at Zacks Investment Research

Akari Therapeutics PLC (NASDAQ:AKTX) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “

AKTX has been the subject of several other reports. ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Canaccord Genuity reissued a “buy” rating and issued a $15.00 target price (down from $33.00) on shares of Akari Therapeutics PLC in a research report on Monday, June 26th. Chardan Capital raised shares of Akari Therapeutics PLC from a “sell” rating to a “neutral” rating and decreased their target price for the stock from $6.50 to $6.00 in a research report on Wednesday, May 31st. Finally, William Blair raised shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a research report on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Akari Therapeutics PLC currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) traded down 2.34% during trading on Tuesday, hitting $7.11. 468,909 shares of the stock were exchanged. The stock’s market cap is $83.73 million. Akari Therapeutics PLC has a 12-month low of $3.18 and a 12-month high of $22.20. The stock’s 50 day moving average is $4.17 and its 200-day moving average is $7.23.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2017/09/26/akari-therapeutics-plc-aktx-rating-lowered-to-hold-at-zacks-investment-research-2.html.

An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent quarter. Institutional investors and hedge funds own 26.85% of the company’s stock.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on t

According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “

AKTX has been the subject of several other reports. ValuEngine raised shares of Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Monday, September 11th. Canaccord Genuity reissued a “buy” rating and issued a $15.00 target price (down from $33.00) on shares of Akari Therapeutics PLC in a research report on Monday, June 26th. Chardan Capital raised shares of Akari Therapeutics PLC from a “sell” rating to a “neutral” rating and decreased their target price for the stock from $6.50 to $6.00 in a research report on Wednesday, May 31st. Finally, William Blair raised shares of Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a research report on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Akari Therapeutics PLC currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) traded down 2.34% during trading on Tuesday, hitting $7.11. 468,909 shares of the stock were exchanged. The stock’s market cap is $83.73 million. Akari Therapeutics PLC has a 12-month low of $3.18 and a 12-month high of $22.20. The stock’s 50 day moving average is $4.17 and its 200-day moving average is $7.23.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2017/09/26/akari-therapeutics-plc-aktx-rating-lowered-to-hold-at-zacks-investment-research-2.html.

An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent quarter. Institutional investors and hedge funds own 26.85% of the company’s stock.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply